SCICLONE PHARMACEUTICALS INC - FORM 10-K - EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - March 31, 2011

Attached files

file filename
10-K - FORM 10-K - SCICLONE PHARMACEUTICALS INCd10k.htm
EX-10.29 - AMENDMENT NO. 1 TO MANUFACTURING AND SUPPLY AGREEMENT - SCICLONE PHARMACEUTICALS INCdex1029.htm
EX-10.28 - ASSIGNMENT AND PURCHASE OF INTELLECTUAL PROPERTY RIGHTS AGREEMENT - SCICLONE PHARMACEUTICALS INCdex1028.htm
EX-10.34 - AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT - DR. FRIEDHELM BLOBEL - SCICLONE PHARMACEUTICALS INCdex1034.htm
EX-10.30 - EXECUTIVE SEVERANCE AGREEMENT - GARY TITUS - SCICLONE PHARMACEUTICALS INCdex1030.htm
EX-10.32 - EXECUTIVE SEVERANCE AGREEMENT - ISRAEL RIOS, M.D. - SCICLONE PHARMACEUTICALS INCdex1032.htm
EX-10.31 - EXECUTIVE SEVERANCE AGREEMENT - HANS P. SCHMID - SCICLONE PHARMACEUTICALS INCdex1031.htm
EX-32.2 - SECTION 1350 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER - SCICLONE PHARMACEUTICALS INCdex322.htm
EX-32.1 - SECTION 1350 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER - SCICLONE PHARMACEUTICALS INCdex321.htm
EX-21.1 - SUBSIDIARIES OF REGISTRANT - SCICLONE PHARMACEUTICALS INCdex211.htm
EX-31.1 - RULE 13A-14(A) CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER - SCICLONE PHARMACEUTICALS INCdex311.htm
EX-31.2 - RULE 13A-14(A) CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER - SCICLONE PHARMACEUTICALS INCdex312.htm
EX-10.35 - AMENDMENT NO. 1 TO CHANGE OF CONTROL AGREEMENT - GARY S. TITUS - SCICLONE PHARMACEUTICALS INCdex1035.htm
EX-10.36 - AMENDMENT NO. 1 TO CHANGE OF CONTROL AGREEMENT - HANS P. SCHMID - SCICLONE PHARMACEUTICALS INCdex1036.htm
EX-10.37 - AMENDMENT NO. 1 TO CHANGE OF CONTROL AGREEMENT - ISRAEL RIOS, M.D. - SCICLONE PHARMACEUTICALS INCdex1037.htm
EX-10.33 - AMENDMENT NO. 2 TO CHANGE OF CONTROL AGREEMENT - DR. FRIEDHELM BLOBEL - SCICLONE PHARMACEUTICALS INCdex1033.htm

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

 

  (1) Registration Statements (Form S-3 Nos. 333-52471, 333-62309, 333-77543, 333-81481, 333-84487, 333-85673, 333-30938, 333-72798, 333-72800, 333-107538, 333-38773, and 333-159364) of SciClone Pharmaceuticals, Inc., and in the related prospectuses,

 

  (2) Registration Statement (Form S-8 No. 333-145281) pertaining to the 2005 Equity Incentive Plan and the 2004 Outside Directors Stock Option Plan of SciClone Pharmaceuticals, Inc.,

 

  (3) Registration Statement (Form S-8 No. 333-128482) pertaining to the 2005 Equity Incentive Plan and the 2004 Outside Directors Stock Option Plan of SciClone Pharmaceuticals, Inc.,

 

  (4) Registration Statement (Form S-8 No. 333-120008) pertaining to the 2004 Stock Option Plan and the 2004 Outside Directors Stock Option Plan of SciClone Pharmaceuticals, Inc.,

 

  (5) Registration Statement (Form S-8 No. 33-109256) pertaining to the 1996 Employee Stock Purchase Plan of SciClone Pharmaceuticals, Inc.,

 

  (6) Registration Statement (Form S-8 No. 333-66832) pertaining to the 1991 Stock Plan, the 1992 Stock Plan, the 1996 Employee Stock Purchase Plan, the 1995 Equity Incentive Plan, and the 1995 Nonemployee Director Stock Option Plan of SciClone Pharmaceuticals, Inc.,

 

  (7) Registration Statement (Form S-8 No. 333-98081) pertaining to the 1995 Equity Incentive Plan and the 1995 Nonemployee Director Stock Option Plan of SciClone Pharmaceuticals, Inc.,

 

  (8) Registration Statement (Form S-8 No. 333-45820) pertaining to the 1995 Equity Incentive Plan and the 1995 Nonemployee Director Stock Option Plan of SciClone Pharmaceuticals, Inc.,

 

  (9) Registration Statement (Form S-8 No. 333-62059) pertaining to the 1995 Equity Incentive Plan of SciClone Pharmaceuticals, Inc.;

 

  (10) Registration Statements (Form S-8 No. 333-12169) pertaining to the 1996 Employee Stock Purchase Plan of SciClone Pharmaceuticals, Inc., and

 

  (11) Registration Statements (Form S-8 No. 333-168668) pertaining to the 2005 Equity Incentive Plan and the Sciclone Pharmaceuticals Inc. Employee Stock Purchase Plan.

of our reports dated March 31, 2011, with respect to the consolidated financial statements and schedule of SciClone Pharmaceuticals, Inc., and the effectiveness of internal control over financial reporting of SciClone Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2010.

/s/ Ernst & Young LLP

Palo Alto, California

March 31, 2011

SCICLONE PHARMACEUTICALS INC Reports

Also read